Advertisement

New Promises in the Adjuvant, and Palliative Treatment of Melanoma

  • Claus Garbe
  • Selma Ugurel
  • Katharina C. Kähler
  • Axel Hauschild
  • Dirk Schadendorf
Part of the Cancer Treatment and Research book series (CTAR, volume 135)

In the last decade the incidence of melanoma has been increasing. Malignant melanoma of the skin is the most frequent cause of mortality from skin cancer. Despite exhaustive efforts to increase early detection and in prevention campaigns, 20–25% of all melanoma patients will die due to disseminated metastases. Once melanoma has spread to regional lymph nodes, survival diminishes to approximately 30–55%. After dissemination to visceral organs, only very few patients can be cured. The median survival with stage IV (AJCC classification) disseminated melanoma is approximately 6–12 months. To date, therapy of disseminated melanoma still has failed to show a significant impact on overall survival. In the adjuvant setting interferon-α is until today the only drug which has shown beneficial effects in high-risk cutaneous melanoma patients. In addition to the development of new targeted drugs the identification of patient subgroups with anticipated benefit will be of importance.

Keywords

Clin Oncol Melanoma Patient Chemosensitivity Testing Chemosensitivity Assay Adjuvant Interferon 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Kirkwood JM, Resnick GD, Cole BF (1997) Efficacy, safety, and risk-benefit analysis of adjuvant interferon alfa-2b in melanoma. Semin Oncol 24: S16–S23.PubMedGoogle Scholar
  2. 2.
    Legha SS (1997) The role of interferon alfa in the treatment of metastatic melanoma. Semin Oncol 24: S24–S31.PubMedGoogle Scholar
  3. 3.
    Garbe C, Krasagakis K, Zouboulis CC, Schroder K, Kruger S, Stadler R, Orfanos CE (1990) Antitumor activities of interferon alpha, beta, and gamma and their combinations on human melanoma cells in vitro: changes of proliferation, melanin synthesis, and immunophenotype. J Invest Dermatol 95: 231S–237S.PubMedCrossRefGoogle Scholar
  4. 4.
    Garbe C, Krasagakis K (1993) Effects of interferons and cytokines on melanoma cells. J Invest Dermatol 100: 239S–244S.PubMedCrossRefGoogle Scholar
  5. 5.
    Horikoshi T, Fukuzawa K, Hanada N, Ezoe K, Eguchi H, Hamaoka S, Tsujiya H, Tsukamoto T (1995) In vitro comparative study of the antitumor effects of human interferon-alpha, beta and gamma on the growth and invasive potential of human melanoma cells. J Dermatol 22: 631–636.PubMedGoogle Scholar
  6. 6.
    Le Page C, Genin P, Baines MG, Hiscott J (2000) Interferon activation and innate immunity. Rev Immunogenet 2: 374–386.PubMedGoogle Scholar
  7. 7.
    Garbe C, Kreuser ED, Zouboulis CC, Stadler R, Orfanos CE (1992) Combined treatment of metastatic melanoma with interferons and cytotoxic drugs. Semin Oncol 19: 63–69.PubMedGoogle Scholar
  8. 8.
    Garbe C (1993) Chemotherapy and chemoimmunotherapy in disseminated malignant melanoma. Melanoma Res 3: 291–299.PubMedGoogle Scholar
  9. 9.
    Lau JF, Horvath CM (2002) Mechanisms of Type I interferon cell signaling and STAT-mediated transcriptional responses. Mt Sinai J Med 69: 156–168.PubMedGoogle Scholar
  10. 10.
    Caraglia M, Marra M, Pelaia G, Maselli R, Caputi M, Marsico SA, Abbruzzese A (2005) Alpha-interferon and its effects on signal transduction pathways. J Cell Physiol 202: 323–335.PubMedCrossRefGoogle Scholar
  11. 11.
    Platanias LC (2005) Mechanisms of type-I- and type-II-interferon-mediated signalling. Nat Rev Immunol 5: 375–386.PubMedCrossRefGoogle Scholar
  12. 12.
    Glue P, Fang JW, Rouzier-Panis R, Raffanel C, Sabo R, Gupta SK, Salfi M, Jacobs S (2000) Pegylated interferon-alpha2b: pharmacokinetics, pharmacodynamics, safety, and preliminary efficacy data. Hepatitis C Intervention Therapy Group. Clin Pharmacol Ther 68: 556–567.PubMedCrossRefGoogle Scholar
  13. 13.
    Motzer RJ, Rakhit A, Ginsberg M, Rittweger K, Vuky J, Yu R, Fettner S, Hooftman L (2001) Phase I trial of 40-kd branched pegylated interferon alfa-2a for patients with advanced renal cell carcinoma. J Clin Oncol 19: 1312–1319.PubMedGoogle Scholar
  14. 14.
    Baker DE (2003) Pegylated interferon plus ribavirin for the treatment of chronic hepatitis C. Rev Gastroenterol Disord 3: 93–109.PubMedGoogle Scholar
  15. 15.
    Fried MW, Shiffman ML, Reddy KR, Smith C, Marinos G, Goncales FL, Jr., Haussinger D, Diago M, Carosi G, Dhumeaux D, Craxi A, Lin A, Hoffman J, Yu J (2002) Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. N Engl J Med 347: 975–982.PubMedCrossRefGoogle Scholar
  16. 16.
    Heathcote EJ, Shiffman ML, Cooksley WG, Dusheiko GM, Lee SS, Balart L, Reindollar R, Reddy RK, Wright TL, Lin A, Hoffman J, De Pamphilis J (2000) Peginterferon alfa-2a in patients with chronic hepatitis C and cirrhosis. N Engl J Med 343: 1673–1680.PubMedCrossRefGoogle Scholar
  17. 17.
    Manns MP, McHutchison JG, Gordon SC, Rustgi VK, Shiffman M, Reindollar R, Goodman ZD, Koury K, Ling M, Albrecht JK (2001) Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial. Lancet 358: 958–965.PubMedCrossRefGoogle Scholar
  18. 18.
    Marcellin P, Lau GK, Bonino F, Farci P, Hadziyannis S, Jin R, Lu ZM, Piratvisuth T, Germanidis G, Yurdaydin C, Diago M, Gurel S, Lai MY, Button P, Pluck N (2004) Peginterferon alfa-2a alone, lamivudine alone, and the two in combination in patients with HBeAg-negative chronic hepatitis B. N Engl J Med 351: 1206–1217.PubMedCrossRefGoogle Scholar
  19. 19.
    Zeuzem S, Feinman SV, Rasenack J, Heathcote EJ, Lai MY, Gane E, O’Grady J, Reichen J, Diago M, Lin A, Hoffman J, Brunda MJ (2000) Peginterferon alfa-2a in patients with chronic hepatitis C. N Engl J Med 343: 1666–1672.PubMedCrossRefGoogle Scholar
  20. 20.
    Baccarani M, Martinelli G, Rosti G, Trabacchi E, Testoni N, Bassi S, Amabile M, Soverini S, Castagnetti F, Cilloni D, Izzo B, de Vivo A, Messa E, Bonifazi F, Poerio A, Luatti S, Giugliano E, Alberti D, Fincato G, Russo D, Pane F, Saglio G (2004) Imatinib and pegylated human recombinant interferon-alpha2b in early chronic-phase chronic myeloid leukemia. Blood 104: 4245–4251.PubMedCrossRefGoogle Scholar
  21. 21.
    Bukowski R, Ernstoff MS, Gore ME, Nemunaitis JJ, Amato R, Gupta SK, Tendler CL (2002) Pegylated interferon alfa-2b treatment for patients with solid tumors: a phase I/II study. J Clin Oncol 20: 3841–3849.PubMedCrossRefGoogle Scholar
  22. 22.
    Motzer RJ, Rakhit A, Thompson J, Gurney H, Selby P, Figlin R, Negrier S, Ernst S, Siebels M, Ginsberg M, Rittweger K, Hooftman L (2002) Phase II trial of branched peginterferon-alpha 2a (40 kDa) for patients with advanced renal cell carcinoma. Ann Oncol 13: 1799–1805.PubMedCrossRefGoogle Scholar
  23. 23.
    Krepler C, Certa U, Wacheck V, Jansen B, Wolff K, Pehamberger H (2004) Pegylated and conventional interferon-alpha induce comparable transcriptional responses and inhibition of tumor growth in a human melanoma SCID mouse xenotransplantation model. J Invest Dermatol 123: 664–669.PubMedCrossRefGoogle Scholar
  24. 24.
    Certa U, Wilhelm-Seiler M, Foser S, Broger C, Neeb M (2003) Expression modes of interferon-alpha inducible genes in sensitive and resistant human melanoma cells stimulated with regular and pegylated interferon-alpha. Gene 315: 79–86.PubMedCrossRefGoogle Scholar
  25. 25.
    Grob JJ, Dreno B, de la SP, Delaunay M, Cupissol D, Guillot B, Souteyrand P, Sassolas B, Cesarini JP, Lionnet S, Lok C, Chastang C, Bonerandi JJ (1998) Randomised trial of interferon alpha-2a as adjuvant therapy in resected primary melanoma thicker than 1.5 mm without clinically detectable node metastases. French Cooperative Group on Melanoma. Lancet 351: 1905–1910.Google Scholar
  26. 26.
    Kirkwood JM, Strawderman MH, Ernstoff MS, Smith TJ, Borden EC, Blum RH (1996) Interferon alfa-2b adjuvant therapy of high-risk resected cutaneous melanoma: the Eastern Cooperative Oncology Group Trial EST 1684. J Clin Oncol 14: 7–17.PubMedGoogle Scholar
  27. 27.
    Kirkwood JM, Ibrahim JG, Sondak VK, Richards J, Flaherty LE, Ernstoff MS, Smith TJ, Rao U, Steele M, Blum RH (2000) High- and low-dose interferon alfa-2b in high-risk melanoma: first analysis of intergroup trial E1690/S9111/C9190. J Clin Oncol 18: 2444–2458.PubMedGoogle Scholar
  28. 28.
    Kirkwood JM, Ibrahim JG, Sosman JA, Sondak VK, Agarwala SS, Ernstoff MS, Rao U (2001) High-dose interferon alfa-2b significantly prolongs relapse-free and overall survival compared with the GM2-KLH/QS-21 vaccine in patients with resected stage IIB-III melanoma: results of intergroup trial E1694/S9512/C509801. J Clin Oncol 19: 2370–2380.PubMedGoogle Scholar
  29. 29.
    Pehamberger H, Soyer HP, Steiner A, Kofler R, Binder M, Mischer P, Pachinger W, Aubock J, Fritsch P, Kerl H, Wolff K (1998) Adjuvant interferon alfa-2a treatment in resected primary stage II cutaneous melanoma. Austrian Malignant Melanoma Cooperative Group. J Clin Oncol 16: 1425–1429.PubMedGoogle Scholar
  30. 30.
    Cameron DA, Cornbleet MC, MacKie RM, Hunter JA, Gore M, Hancock B, Smyth JF (2001) Adjuvant interferon alpha 2b in high risk melanoma - the Scottish study. Br J Cancer 84: 1146–1149.PubMedCrossRefGoogle Scholar
  31. 31.
    Cascinelli N, Belli F, MacKie RM, Santinami M, Bufalino R, Morabito A (2001) Effect of long-term adjuvant therapy with interferon alpha-2a in patients with regional node metastases from cutaneous melanoma: a randomised trial. Lancet 358: 866–869.PubMedCrossRefGoogle Scholar
  32. 32.
    Eggermont AM, Suciu S, MacKie R, Ruka W, Testori A, Kruit W, Punt CJ, Delauney M, Sales F, Groenewegen G, Ruiter DJ, Jagiello I, Stoitchkov K, Keilholz U, Lienard D (2005) Post-surgery adjuvant therapy with intermediate doses of interferon alfa 2b versus observation in patients with stage IIb/III melanoma (EORTC 18952): randomised controlled trial. Lancet 366: 1189–1196.PubMedCrossRefGoogle Scholar
  33. 33.
    Hancock BW, Wheatley K, Harris S, Ives N, Harrison G, Horsman JM, Middleton MR, Thatcher N, Lorigan PC, Marsden JR, Burrows L, Gore M (2004) Adjuvant interferon in high-risk melanoma: the AIM HIGH Study–United Kingdom Coordinating Committee on Cancer Research randomized study of adjuvant low-dose extended-duration interferon Alfa-2a in high-risk resected malignant melanoma. J Clin Oncol 22: 53–61.Google Scholar
  34. 34.
    Lens MB, Dawes M (2002) Interferon alfa therapy for malignant melanoma: a systematic review of randomized controlled trials. J Clin Oncol 20: 1818–1825.PubMedCrossRefGoogle Scholar
  35. 35.
    Wheatley K, Ives N, Hancock B, Gore M (2002) Need for a quantitative meta-analysis of trials of adjuvant interferon in melanoma. J Clin Oncol 20: 4120–4121.PubMedCrossRefGoogle Scholar
  36. 36.
    Wheatley K, Ives N, Hancock B, Gore M, Eggermont A, Suciu S (2003) Does adjuvant interferon-alpha for high-risk melanoma provide a worthwhile benefit? A meta-analysis of the randomised trials. Cancer Treat Rev 29: 241–252.PubMedCrossRefGoogle Scholar
  37. 37.
    Eggermont A (2002) Evaluation of intermediate dose interferon (EORTC 18952) and long-term therapy with PEG-Intron (EORTC 18991) in more than 2000 patients with very high risk melanoma. Melanoma Res 12: A5–A19.CrossRefGoogle Scholar
  38. 38.
    Eigentler TK, Caroli UM, Radny P, et al. (2003) Palliative therapy of disseminated malignant melanoma: a systematic review of 41 randomised clinical trials. Lancet Oncol 4:748–759.PubMedCrossRefGoogle Scholar
  39. 39.
    Keilholz U, Punt CJA, Gore M, Kruit W, Patel P, Lienard D, Thomas J, Proebstle TM, Schmittel A, Schadendorf D, Velu T, Negrier S, Kleeberg U, Lehman F, Suciu S, Eggermont AMM (2005). Dacarbazine, cisplatin and interferon-alpha-2b with or without interleukin-2 in metastatic melanoma: A randomized phase III trial (18951) of the EORTC Melanoma Group. J Clin Oncol 23: 6747–6755.PubMedCrossRefGoogle Scholar
  40. 40.
    Helmbach H, Rossmann E, Kern MA, et al. (2001) Drug-resistance in human melanoma. Int J Cancer 93:617–622.PubMedCrossRefGoogle Scholar
  41. 41.
    Andreotti PE, Cree IA, Kurbacher CM, et al: Chemosensitivity testing of human tumors using a microplate adenosine triphosphate luminescence assay: clinical correlation for cisplatin resistance of ovarian carcinoma. Cancer Res 1995;55:5276–5282.PubMedGoogle Scholar
  42. 42.
    Ugurel S, Schadendorf D, Pföhler C, Neuber K, Thoelke A, Ulrich J, Hauschild A, Spieth K, Kaatz M, Rittgen W, Delorme S, Tilgen W, Reinhold U (2006). In vitro drug sensivity predicts response and survival after individualized sensitivity-directed chemotherapy in metastatic melanoma–a multicenter phase II trial of the Dermatology Cooperative Oncology Group (DeCOG). Clin Cancer Res, 12(18):5454–63.PubMedCrossRefGoogle Scholar
  43. 43.
    Food and Drug Administration Center for Drug Evaluation and Research: Oncologic Drugs Advisory Committee, Briefing Material: May 3, 2004 AM Session - Genasense. http://www.fda.gov/ohrms/dockets/ac/04/briefing/4037B1_02_FDA-Genasense.pdf.
  44. 44.
    Fruehauf JP, Alberts DS: In vitro drug resistance versus chemosensitivity: two sides of different coins. J Clin Oncol 2005;23:3641–3643.PubMedCrossRefGoogle Scholar
  45. 45.
    Wiegand HS: Chemotherapy sensitivity and response assays: are the ASCO guidelines for clinical trial design too restrictive? J Clin Oncol 2005;23:3643–3644.CrossRefGoogle Scholar
  46. 46.
    Castro M: Resisting a fundamentalist policy. J Clin Oncol 2005;23:3645–3646.PubMedCrossRefGoogle Scholar
  47. 47.
    Cheson BD: Individualizing therapy for the hematologic malignancies: the stuff of genes and dreams. J Clin Oncol 23: 6283–6284, 2005.PubMedCrossRefGoogle Scholar
  48. 48.
    Lu J, Getz G, Miska EA, Alvarez-Saavedra E, Lamb J, Peck D, Sweet-Cordero A, Ebert BL, Mak RH, Ferrando AA, Downing JR, Jacks T, Horvitz HR, Golub TR: MicroRNA expression profiles classify human cancers. Nature 435:834–838, 2005.PubMedCrossRefGoogle Scholar
  49. 49.
    Mian S, Ugurel S, Parkinson E, Schlenzka I, Dryden I, Lancashire L, Ball G, Creaser C, Rees R, Schadendorf D: Serum proteomic fingerprinting discriminates between clinical stages and predicts disease progression in melanoma patients. J Clin Oncol 23: 5088–5093, 2005.PubMedCrossRefGoogle Scholar
  50. 50.
    Jansen B, Schlagbauer-Wadl H, Brown BD: Bcl-2 antisense therapy chemosensitizes human melanoma in SCID mice. Nat Med 4:232–234, 1998.PubMedCrossRefGoogle Scholar
  51. 51.
    Jansen B, Wacheck V, Heere-Ress E, Schlagbauer-Wadl H, Hoeller C, Lucas T, Hoermann M, Hollenstein U, Wolff K, Pehamberger H: Cehmosensitisation of malignant melanoma by BCL2 antisense therapy. Lancet 356: 1728–1733, 2000.PubMedCrossRefGoogle Scholar
  52. 52.
    Pao W, Miller VA: Epidermal growth factor receptor mutations, small-molecule kinase inhibitors, and non-small-cell lung cancer: current knowledge and future directions. J Clin Oncol 23: 2556–2568, 2005.PubMedCrossRefGoogle Scholar
  53. 53.
    Davies H, Bignell GR, Cox C, Stephens P, Edkins S, Clegg S: Mutations of the BRAF gene in human cancer. Nature 417: 949–954, 2002.PubMedCrossRefGoogle Scholar
  54. 54.
    Margolin K, Longmate J, Baratta T, Synold T, Christensen S, Weber J, Gajewski T, Quirt I, Doroshow JH: Cancer 104: 1045–1048, 2005.PubMedCrossRefGoogle Scholar
  55. 55.
    Mani A, Gelmann EP: The ubiquitin-proteasome pathway and its role in cancer. J Clin Oncol 21: 4776–4789, 2005.CrossRefGoogle Scholar
  56. 56.
    Markovic SN, Geyer SM, Dawkins F, Sharfman W, Albertini M, Maples W: A phase II study of bortezomib in the treatment of metastatic malignant melanoma. Cancer 103: 2584–2589, 2005.PubMedCrossRefGoogle Scholar
  57. 57.
    Ryan QC, Headlee D, Acharya M, Sparreboom A, Trepel JB, Ye J: Phase I and pharmacokinetic study of MS-275, a histone deacetylase inhibitor, in patients with advanced and refractory solid tumors or lymphoma. J Clin Oncol 23: 3912–3922, 2005.PubMedCrossRefGoogle Scholar
  58. 58.
    Gasparini G, Longo R, Fanelli M, Teicher BA: Combination of antiangiogenic therapy with other anticancer therapies: results, challenges, and open questions.Google Scholar
  59. 59.
    Hwu WJ, Lis E, Menell JH, Panageas KS, Lamb LA, Merrell J: Temozolomide plus thalidomide in patients with brain metastases from melanoma: a phase II study. Cancer 103: 2590–2597, 2005.PubMedCrossRefGoogle Scholar
  60. 60.
    Miller KD, Chap LI, Holmes FA, Cobleigh MA, Marcom PK, Fehrenbacher L: Randomized phase III trial of capecitabine compared with bevacizumab plus capecitabine in patients with previously treated metastatic breast cancer. J Clin Oncol 23: 792–799, 2005.PubMedCrossRefGoogle Scholar
  61. 61.
    Hersey P, Sosman J, O’Day S, Richards J, Bedikian, Gonzalez R, Sharfman W, Weber R, Logan T, Kirkwood JM: A phase II, randomized, open-label study evaluating the antitumor activity of MEDI-522, a humanized monoclonal antibody directed against the human alpha v beta 3 8avb3) integrin ± dacarbazine (DTIC) in patients with metastatic melanoma (MM). J Clin Oncol 23, Suppl 16S: 711, 2005 (Abstract).Google Scholar

Copyright information

© Springer Science+Business Media, LLC 2007

Authors and Affiliations

  • Claus Garbe
    • 1
  • Selma Ugurel
    • 2
  • Katharina C. Kähler
    • 3
  • Axel Hauschild
    • 3
  • Dirk Schadendorf
    • 2
  1. 1.Department of DermatologyUniversity Medical CenterGermany
  2. 2.German Cancer Research Centre and University Hospital MannheimUniversity of HeidelbergGermany
  3. 3.Department of DermatologyUniversity of KielGermany

Personalised recommendations